News - Proxygen

Proxygen announces collaboration and license agreement with MSD

05 April 2023 | Proxygen, a leader in the discovery and development of molecular glue degraders, announced today a multi-year research collaboration and license agreement with Merck & Co Inc., Rahway, N.J., USA, known as MSD outside the U.S. and Canada, to jointly identify and develop molecular glue degraders […]

Proxygen announces formation of board of directors

15 March 2023 | Proxygen, a leader in the discovery and development of molecular glue degraders, today announced the formation of the company’s board of directors. The newly appointed board of independent directors, […]

Proxygen announces strategic collaboration with Merck

02 June 2022 | Proxygen, a leader in the discovery and development of molecular glue degraders, announced today that the company has entered into a strategic multi-year research collaboration and license agreement with Merck. […]

Boehringer Ingelheim collaborates with Proxygen

07 December 2020 | Boehringer Ingelheim and Proxygen today announced they have entered into a collaboration and license agreement to enable the identification of molecular glue degraders against various oncogenic targets. The collaboration combines […]

Boehringer Ingelheim awards Proxygen with BI Innovation Prize

31 July 2020 | The young biotech company Proxygen yesterday received the BI Innovation Prize for 12 months of free office and lab space in the new Start-Up Labs incubator at the Vienna BioCenter, […]